Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
CVP
Regimen is considered appropriate as part of the standard care of patients; meaningfully improves outcomes (survival, quality of life), tolerability or costs compared to alternatives (recommended by the Disease Site Team and national consensus body e.g. pan-Canadian Oncology Drug Review, pCODR). Recommendation is based on an appropriately conducted phase III clinical trial relevant to the Canadian context OR (where phase III trials are not feasible) an appropriately sized phase II trial. Regimens where one or more drugs are not approved by Health Canada for any indication will be identified under Rationale and Use.
First-line/salvage therapy for indolent lymphoma
prednisone
ODB - General Benefit
(prednisone)
(ODB Formulary
)
| cyclophosphamide | 750 mg /m² | IV | Day 1 |
| vinCRIStine | 1.4 mg /m² | IV (maximum 2 mg) | Day 1 |
| prednisone | 100 mg | PO | Days 1 to 5 |
|
(outpatient prescription in 50 mg tablets) |
|||
REPEAT EVERY 21 DAYS
For a usual total of 6 to 8 cycles unless disease progression or unacceptable toxicity occurs
Doses should be modified according to the protocol by which the patient is being treated.
Dosage with toxicity
| Toxicity | Vincristine1 (% previous dose) | Cyclophosphamide1 (% previous dose) |
| Grade 4 hematological ≥ 7 d, febrile neutropenia, bleeding | 100% | 75% or G-CSF for low ANC |
| Grade 3 non-hematological toxicity | 100% | 75% |
| Grade 4 organ toxicity | Discontinue | Discontinue |
| Neurotoxicity | Mild: 67% Moderate: Hold until recovery, then ↓ 50% Severe: Discontinue |
100% |
Hepatic Impairment
Also consider dose modification for vincristine for severe increase in transaminases.
| Bilirubin | Vincristine (% previous dose) |
Cyclophosphamide (% previous dose) |
|
1 – 2 X ULN |
50%
|
100% |
|
2 – 4 x ULN |
25%
|
Caution |
|
> 4 ULN |
OMIT
|
Caution |
Renal Impairment
| Creatinine Clearance (mL/min) | Vincristine (% previous dose) |
Cyclophosphamide (% previous dose) |
|
>30-50
|
No dose adjustment required. |
100%
|
|
10-30
|
50-75%
|
|
|
< 10 |
50% or Omit |
Refer to cyclophosphamide, vinCRIStine, prednisone drug monograph(s) for additional details of adverse effects
|
Most Common Side Effects |
Less Common Side Effects, but may be Severe |
|
|
Refer to cyclophosphamide, vinCRIStine, prednisone drug monograph(s) for additional details
Refer to cyclophosphamide, vinCRIStine, prednisone drug monograph(s) for additional details
Recommended Clinical Monitoring
- CBC; baseline and before each cycle. Interim counts should be done in first cycle and repeated if dose modification necessary.
- Blood glucose testing; baseline and regular
- Baseline and regular liver & renal function tests and urinalysis.
- Clinical toxicity assessment (including gastrointestinal, neurotoxicity, constipation and cystitis); at each visit
-
Grade toxicity using the current NCI-CTCAE (Common Terminology Criteria for Adverse Events) version
back to top
Bagley CM, DeVita VT, et al. Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine and prednisone. Ann Int Med, 1972; 76: 227-234.
Cyclophosphamide, vincristine drug monographs, Cancer Care Ontario.
Hochster H, Weller E, Gascoyne RD, et al. Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study. J Clin Oncol 2009; 27: 1607-14.
Klasa RJ, Meyer RM, Shustik C, et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin’s lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol 2002;20:4649-4654.
Luce JK, et al. COP therapy of malignant lymphoma. Cancer, 1971; 26(2): 306-317.
Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105(4):1417-23.
July 2019 Updated hyperlink to vincristine drug monograph
Regimen Abstracts
A Regimen Abstract is an abbreviated version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). It is intended for healthcare providers and is to be used for informational purposes only. It is not intended to constitute or be a substitute for medical advice, and all uses of the Regimen Abstract are subject to clinical judgment. Such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability, and Cancer Care Ontario disclaims all liability for the use of this information, and for any claims, actions, demands or suits that arise from such use.
Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph. Full regimen monographs will be published for each ST-QBP regimen as they are developed.
Regimen Monographs
Refer to the New Drug Funding Program or Ontario Public Drug Programs websites for the most up-to-date public funding information.
The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.
The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.
Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.
While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.
CCO and the Formulary’s content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the Formulary.